Oleuropein
CAS 32619-42-4
Oleuropein (CAS 32619-42-4) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 47788.524 nM | 4 | - |
| - | EC50 | 11705 nM | 2 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TAS2R8 TAS2R8 |
Agonist | 4.239999771118164 pEC50 | 34785711 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| OLEUROPEIN | 2376830 | SU | MTHSPL |
| oleuropein | 2376830 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Oleuropein used for in pharmaceutical contexts?
Oleuropein (CAS 32619-42-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Oleuropein?
No adverse-event association or SIDER side-effect rows are rendered for Oleuropein in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Oleuropein also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Oleuropein with EU status "permitted".
What clinical phase is Oleuropein in?
No phase 1-4 clinical development badge is rendered for Oleuropein because the matched compound identifier rows do not contain a max-phase value.